目的 探讨三味檀香胶囊联合阿替洛尔治疗心绞痛的临床疗效。方法 2018年4月-2019年4月在武汉大学人民医院进行治疗的94例心绞痛患者，根据用药差异分成对照组和治疗组，每组各47例。对照组患者口服阿替洛尔片，起始12.5 mg/次，2次/d，根据需要及耐受量可增至50 mg/次，2次/d。治疗组患者在对照组基础上口服三味檀香胶囊，0.6 g/次，3次/d。两组均经4周治疗后进行效果比较。观察两组的临床疗效，比较两组治疗前后临床症状改善时间、相关评分、血液流变学指标和血清学指标的变化情况。结果 治疗后，对照组和治疗组临床有效率分别为80.85%和95.74%，两组比较差异有统计学意义（P<0.05）。治疗后，两组心绞痛发作次数显著降低，持续时间显著缩短，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组患者心绞痛发作次数显著低于对照组，持续时间显著短于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组SF-36量表积分、SAQ积分均显著增高，而临床症状积分均显著降低（P<0.05）；治疗后，治疗组SF-36量表积分、SAQ积分显著高于对照组，而临床症状积分显著低于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组全血黏度（WBV）、血浆黏度（PV）、纤维蛋白原（FIB）和血小板黏附率（PAR）水平均降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组这些血液流变学指标显著低于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组血清脂蛋白磷脂酶A2（Lp-PLA2）、重组人可溶性CD40配体（sCD40L）、S100钙结合蛋白A12（S100A12）、髓过氧化物酶（MPO）、白细胞介素-6（IL-6）水平均降低，同组治疗前后比较差异有统计学意义（P<0.05）；治疗后，治疗组这些血清学指标显著低于对照组，两组比较差异有统计学意义（P<0.05）。结论 三味檀香胶囊联合阿替洛尔治疗心绞痛具有较好的临床疗效，可明显改善患者临床症状，改善机体血液流变学指标，降低血清学指标水平，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Sanwei Tanxiang Capsules combined with atenolol in treatment of angina pectoris. Methods Patients (94 cases) with angina pectoris in Renmin Hospital of Wuhan University from April 2018 to April 2019 were divided into control group (47 cases) and treatment group (47 cases) according to the difference of medication. Patients in the control group were po administered with Atenolol Tablets, started at 12.5 mg/time, twice daily, and this could be increased to 50 mg/time as required and tolerated. Patients in the treatment group were po administered with Sanwei Tanxiang Capsules on the basis of the control group, 0.6 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptom improvement time, correlation scores, hemorheology indexes and serological indexes in two groups were compared. Results After treatment, the effective rate of the control group was 80.85%, significantly lower than that of the treatment group (95.74%, P<0.05). The frequency and duration of angina pectoris were significantly reduced in the two groups, and there were differences in the same group (P<0.05). After treatment, the frequency of angina pectoris in the treatment group was significantly lower than that in the control group, and the duration was significantly shorter than that in the control group, and there were differences between two groups (P<0.05). After treatment, SF-36 score and SAQ score were significantly increased in both groups, while the clinical symptoms scores were significantly decreased (P<0.05). After treatment, SF-36 score and SAQ score in the treatment group were significantly higher than those in the control group, while the clinical symptoms scores were significantly lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, WBV, PV, FIB, and PAR in two groups were significantly decreased, and there were differences in the same group (P<0.05). After treatment, those hemorheological indexes in the treatment group were lower than those in the control group, and there were differences between two groups (P<0.05). After treatment, Lp-PLA2, sCD40L, S100A12, MPO, and IL-6 in the control group were significantly decreased, and there were differences in the same group (P<0.05). After treatment, the serological indexes in the treatment group were lower than those in the control group, and there were differences between two groups (P<0.05). Conclusion Sanwei Tanxiang Capsules combined with atenolol has good clinical effect in treatment of angina pectoris, and can significantly improve the clinical symptoms of patients, improve hemorheology indicators of the body, and reduce the level of serological indicators, which has a certain clinical application value.

R972